Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients

Dormant cancer cells that survive anti-cancer therapy can lead to cancer recurrence and disseminated metastases that prove fatal in most cases. Recently, specific dormant polyploid giant cancer cells (PGCC) have drawn the investigators' attention because of their association with the clinical risk of nasopharyngeal carcinoma (NPC) recurrence, as demonstrated by previous clinical data. In study, the investigators report the biological properties of PGCC, and reveal that autophagy is a critical mechanism of PGCC induction. Moreover, pharmacological inhibition of autophagy greatly impaired PGCC f

Trial Details

NCT ID
NCT06389201
Phase
NA
Sponsor
Affiliated Hospital of Nantong University
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • HCQ
  • Placebo
Locations (sample)
  • Nantong, Jiangsu, China|32.03028,120.87472

Key Eligibility Criteria

  • Clinical diagnosis of NPC.
  • Have not received any cancer therapies
  • Must provide informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →